Literature DB >> 24630997

Asymmetric reprogramming capacity of parental pronuclei in mouse zygotes.

Wenqiang Liu1, Jiqing Yin2, Xiaochen Kou2, Yonghua Jiang3, Haibo Gao3, Yanhong Zhao2, Bo Huang3, Wenteng He2, Hong Wang4, Zhiming Han5, Shaorong Gao6.   

Abstract

It has been demonstrated that reprogramming factors are sequestered in the pronuclei of zygotes after fertilization, because zygotes enucleated at the M phase instead of interphase of the first mitosis can support the development of cloned embryos. However, the contribution of the parental pronucleus derived from either the sperm or the oocyte in reprogramming remains elusive. Here, we demonstrate that the parental pronuclei have asymmetric reprogramming capacities and that the reprogramming factors reside predominantly in the male pronucleus. As a result, only female pronucleus-depleted (FPD) mouse zygotes can reprogram somatic cells to a pluripotent state and support the full-term development of cloned embryos; male pronucleus-depleted (MPD) zygotes fail to support somatic cell reprogramming. We further demonstrate that fusion of an additional male pronucleus into a zygote greatly enhances reprogramming efficiency. Our data provide a clue to further identify critical reprogramming factors in the male pronucleus.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24630997     DOI: 10.1016/j.celrep.2014.02.018

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  13 in total

1.  Presence of the Paternal Pronucleus Assists Embryo in Overcoming Cycloheximide Induced Abnormalities in Zygotic Mitosis.

Authors:  Michael A Ortega; Myungjun Ko; Joel Marh; Ariel Finberg; Marissa Oshiro; W Steven Ward
Journal:  J Cell Biochem       Date:  2016-01-21       Impact factor: 4.429

2.  Paternal H3K4 methylation is required for minor zygotic gene activation and early mouse embryonic development.

Authors:  Keisuke Aoshima; Erina Inoue; Hirofumi Sawa; Yuki Okada
Journal:  EMBO Rep       Date:  2015-04-29       Impact factor: 8.807

Review 3.  5-Hydroxymethylcytosine: a stable or transient DNA modification?

Authors:  Maria A Hahn; Piroska E Szabó; Gerd P Pfeifer
Journal:  Genomics       Date:  2014-08-30       Impact factor: 5.736

Review 4.  Reprogramming the genome to totipotency in mouse embryos.

Authors:  Li-quan Zhou; Jurrien Dean
Journal:  Trends Cell Biol       Date:  2014-10-21       Impact factor: 20.808

Review 5.  Maternal histone variants and their chaperones promote paternal genome activation and boost somatic cell reprogramming.

Authors:  Peng Yang; Warren Wu; Todd S Macfarlan
Journal:  Bioessays       Date:  2014-10-18       Impact factor: 4.345

6.  Parental competition for the regulators of chromatin dynamics in mouse zygotes.

Authors:  Masatoshi Ooga; Rei Inoue; Kousuke Kazama; Sayaka Wakayama; Satoshi Kamimura; Teruhiko Wakayama
Journal:  Commun Biol       Date:  2022-07-14

7.  Cell totipotency: molecular features, induction, and maintenance.

Authors:  Falong Lu; Yi Zhang
Journal:  Natl Sci Rev       Date:  2015-06       Impact factor: 17.275

8.  Nucleus reprogramming/remodeling through selective enucleation (SE) of immature oocytes and zygotes: a nucleolus point of view.

Authors:  Helena Fulka; Pasqualino Loi; Luca Palazzese; Michal Benc; Josef Fulka Jr
Journal:  J Reprod Dev       Date:  2022-04-17       Impact factor: 2.215

9.  Exploring timing activation of functional pathway based on differential co-expression analysis in preimplantation embryogenesis.

Authors:  Yongchun Zuo; Guanghua Su; Shanshan Wang; Lei Yang; Mingzhi Liao; Zhuying Wei; Chunling Bai; Guangpeng Li
Journal:  Oncotarget       Date:  2016-11-08

10.  The Dynamics and Regulatory Mechanism of Pronuclear H3k9me2 Asymmetry in Mouse Zygotes.

Authors:  Xue-Shan Ma; Shi-Bin Chao; Xian-Ju Huang; Fei Lin; Ling Qin; Xu-Guang Wang; Tie-Gang Meng; Cheng-Cheng Zhu; Heide Schatten; Hong-Lin Liu; Qing-Yuan Sun
Journal:  Sci Rep       Date:  2015-12-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.